Abstract: The field of the invention is that of prebiotic compositions. In particular, the invention relates to a prebiotic composition comprising galactoglucomannans, and also the production method thereof. The invention also targets the use of this prebiotic composition for increasing production of short-chain fatty acids by bacteria of the intestinal microbiota.

Abstract: The embodiment of the invention is a virus-like particle vector, a process for the manufacture thereof, use of the virus-like particle vector and a pharmaceutical composition, which contains the virus-like particle vector. The vector is intended for the delivery of therapeutic agents into specific mammalian tissues, especially low molecular weight agents, in particular low molecular weight anti-cancer drugs into cancer tissues. More specifically, the invention relates to the virus-like particle vector, which constitutes an adenoviral dodecahedron with the therapeutic substance encapsulated or covalently linked.

Abstract: Use of VPg proteins, fragments or analogs thereof having the ability to bind an eukaryotic initiation factor eIF4E, for inhibiting cell-proliferation.

Abstract: The embodiment of the invention is a virus-like particle vector, a process for the manufacture thereof, use of the virus-like particle vector and a pharmaceutical composition, which contains the virus-like particle vector. The vector is intended for the delivery of therapeutic agents into specific mammalian tissues, especially low molecular weight agents, in particular low molecular weight anti-cancer drugs into cancer tissues. More specifically, the invention relates to the virus-like particle vector, which constitutes an adenoviral dodecahedron with the therapeutic substance encapsulated or covalently linked.

Abstract: Use of VPg proteins, fragments or analogs thereof having the ability to bind an eukaryotic initiation factor eIF4E, for inhibiting cell-proliferation.

Abstract: The invention concerns transfecting peptide vector, a composition containing said vector and their applications for treating and preventing diseases in human beings and animals. Said vector for transfecting a chemical substance selected in the group consisting of nucleic acid sequences, proteins, peptides and pharmacologically active substances, contains besides said chemical substance, at least a transfecting peptide derived entirely or partially from an adenovirus fibre and comprising at least a zone consisting of at least 50% hydrophobic amino acids selected in the group consisting of alanine, valine, phenylamine, isoleucine, leucine, proline and methionine.

Abstract: A native or recombinant adenoviral protein complex, a pharmaceutical composition containing said protein complex, and the uses thereof for treating and preventing human and animal diseases, are disclosed. Said adenoviral protein complex consists of either 12 pentons each including at least one fiber and a penton base, but no other element from an adenovirus genome, said fiber(s) and said penton base being derived from one or more adenoviruses, said pentons being bound by the penton bases and forming a proteolytic enzyme-stable dodecahedral structure, said complex having a molecular weight between 4.8.times.10.sup.6 and 6.6.times.10.sup.6, and such complexes being known as dodecahedron-penton complexes; or 12 penton bases but no other element from an adenovirus genome, said penton bases being derived from one or more adenoviruses and forming a proteolytic enzyme-stable dodecahedral structure, said complex having a molecular weight between 3.2.times.10.sup.6 and 4.times.10.sup.